

Innovative Oncology Medicines



CHALLENGE

Aenova Responds to Fast Growing Market Demands in Oncology Treatments

- Cancer treatment is developing towards more and more specific pharmacological targets
- Leading to smaller patient groups and small SKUs
- Short project realization timelines are of utmost importance (e.g. breakthrough designations)
- Specific technology needs for HPAPI and poor bioavailability compounds




SOLUTION

Aenova Provides Efficient and Flexible Solutions across the Product Life Cycle

- Flexible manufacturing technology with full scalability for HPAPI products (batch sizes from 0.5 – 500 kg)
- Development solutions with experienced scientists and dedicated resources
- Novel technologies to overcome poor bioavailability are available
- Significant investment in capacity extension for development and manufacturing of high potent solids

The Aenova CDMO offer






EXAMPLE

Aenova's Customer Benefit: Standardized Technology and Agile Solutions

- Aenova is partner of choice for big pharma as well as oncology-focused industry and start-ups
- Full service for innovative NCE from early development to launch and commercial supply
- Commercial supply of niche and break-through therapy for bulk and packaging; Bulk batch size as low as 1 kg for world-wide market supply; 'brite stock' concepts for packaging available



BENEFITS

Aenova Offers One-Stop Shop advantages

Aenova is your partner of choice for development and commercial launch of innovative oncology therapeutics, based on Aenova's one-stop shop approach.

- ✓ Fast project realization from idea to market
- ✓ Minimum project risk
- ✓ Highly cost-effective execution



Aenova Holding GmbH

Berger Straße 8 - 10
 82319 Starnberg
 Germany

✉ info@aenova-group.com

🌐 www.aenova-group.com